Us Fda Accepts Correvios Resubmitted Nda For Brinavess
Correvio Pharma Corp, A Specialty Pharmaceutical Company Focused On Commercializing Hospital Drugs, Announced That The Us Food And Drug Administration (Fda) Has Accepted For Review The Resubmitted New Drug Application (Nda) For Brinavess (Vernakalant Hydrochloride, Iv), An Antiarrhythmic Drug For The Rapid Conversion Of Recent Onset Atrial Fibrillation (Af) To Sinus Rhythm In Adult Patients. The Fda Assigned A Target Action Date Of December 24, 2019 Under The Prescription Drug User-Fee Act (Pdufa). In Its Acceptance Letter, The Fda Stated That It Is Currently Planning To Hold An Advisory Committee Meeting To Discuss This Application.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
